Fubotv earnings beat by $0.10, revenue topped estimates
LONDON - CRISM Therapeutics Corporation (AIM:CRTX) is advancing toward clinical trials for its ChemoSeed drug delivery system following positive feedback from UK regulators, according to a press release statement issued Friday.
The company, which joined AIM in May 2024 through a reverse takeover of Amur Minerals Corporation, reported it received written scientific advice from the Medicines and Healthcare products Regulatory Agency (MHRA) in March 2025 confirming no additional toxicology studies would be needed for its glioblastoma treatment program, saving approximately £400,000.
CRISM plans to submit its Clinical Trial Authorization (CTA) application in the first half of 2025, with trials expected to commence in early 2026 pending regulatory review.
The company reported net cash of £550,000 as of May 31, 2025, down from £1.28 million at the end of December 2024 and £1.95 million in May 2024.
During 2024, CRISM secured additional revenue through a £230,000 service agreement with imphatec limited in July and obtained a £25,000 grant from SPARK Midlands for its glioblastoma treatment research. The company also strengthened its intellectual property position with the granting of an EU patent for ChemoSeed in December 2024.
Post-period developments include winning an Innovate UK grant to explore ChemoSeed applications in prostate cancer treatment and establishing a Scientific Advisory Board to guide its upcoming Phase II clinical trial.
CRISM specializes in localized delivery of chemotherapy drugs and is preparing to begin GMP manufacturing of clinical trial batches of ChemoSeed.
The company appointed specialist brain tumor contract research organization Aixial in December 2024 to advance its CTA application.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.